Stock Comparison

NVO vs PFE

Novo Nordisk A/S vs Pfizer Inc

Who's the better investment? Let's break it down.

The Verdict

PFE takes this one.

PFE edges out the competition with a 2.7-point advantage. Not a blowout, but the numbers favor PFE.

NVO

Novo Nordisk A/S

1.3

out of 10

Distressed

Winner

PFE

Pfizer Inc

4.0

out of 10

Proceed with Caution

Want to compare any two stocks?

Valuation

NVO

Metric

PFE

$1.3T

Market Cap

$146.4B

10.6

P/E Ratio

Lower may indicate better value

19.5

11.9

Forward P/E

8.1

6.3

Price/Book

1.5

7.7

EV/EBITDA

7.1

Profitability & Growth

NVO

Metric

PFE

37.2%

Profit Margin

11.8%

81.8%

Gross Margin

74.8%

45.3%

Operating Margin

15.4%

66.4%

Return on Equity

8.4%

23.3%

Return on Assets

3.6%

8.1%

Revenue Growth

1.4%

$27.41

EPS

$1.31

Financial Health

NVO

Metric

PFE

0.7

Debt-to-Equity

Lower = less leverage

0.7

0.8

Current Ratio

Above 1.0 is healthy

1.2

1.9

Beta

Lower = less volatile

0.3

4.0%

Dividend Yield

6.8%

Risk Comparison

NVO

Overall

Moderate

Financial

Low

Market

Low

Competitive

High

Execution

Medium

Regulatory

Medium

What Could Go Wrong

The biggest risk is sustained and aggressive competition from Eli Lilly and other emerging players in the GLP-1 market, which could continue to pressure realized prices. As evidenced by the Q1 2026 re...

Red Flags

🚩Adjusted sales decline of 4% YoY in Q1 2026 due to lower realized prices, despite strong reported gr...
🚩Adjusted operating profit decline of 6% YoY in Q1 2026, indicating margin compression.
🚩Reliance on the GLP-1 franchise for a significant portion of revenue, making it vulnerable to compet...

PFE

Overall

Moderate

Financial

Low

Market

Low

Competitive

Medium

Execution

Low

Regulatory

Medium

What Could Go Wrong

The biggest risk for Pfizer is the ongoing and accelerated erosion of revenue from key patent expirations and declining COVID-related product sales (Paxlovid/Comirnaty). If the pipeline of new product...

Red Flags

🚩Adjusted EPS declined -18% YoY in Q1 2026 despite revenue beat, indicating continued margin pressure...
🚩High reliance on successful pipeline execution to offset significant revenue declines from mature pr...
🚩Market Cap ($146.42B) requires an unrealistic 10x growth to over $1.4 trillion in 3-5 years, a scale...

Competitive Moat

NVO

Rating

🛡️ Wide

Trend

➡️ Stable, but facing erosion pressure

Intangible Assets (Patents, Brand Power)Cost Advantages (Scale in manufacturing and R&D)Switching Costs (Chronic medication adherence)

PFE

Rating

🛡️ Wide

Trend

➡️ Stable

Intangible Assets/IP (Patents, regulatory approvals, proprietary compounds)Brand Power (Trust, reputation in healthcare)Cost Advantages (Scale in manufacturing and R&D)Switching Costs (Physician familiarity, established treatment protocols)

Investment Thesis

NVO1.3/10

If Novo Nordisk successfully defends its market leadership in the rapidly expanding GLP-1 and obesity markets through continuous innovation, expanded indications, and strategic pricing, then it can sustain double-digit reported revenue growth and gradually improve adjusted profitability, supporting modest share price appreciation. This is bullish for long-term holders seeking stable growth, but it...

Full NVO Analysis

PFE4.0/10

If Pfizer's non-COVID product portfolio (e.g., Vyndaqel, Eliquis, newly launched oncology/rare disease drugs) continues to deliver mid-single-digit operational growth (above +5% YoY) and its late-stage pipeline yields 2-3 significant approvals (>$500M potential) over the next 18-24 months, then it could stabilize revenue around its $60B guidance range and see a modest re-rating to a 12-13x forward...

Full PFE Analysis

Price Targets & Strategy

Price Targets & Entry/Exit Strategy

Growth Catalysts

Growth Catalysts Comparison

Market Sentiment

Market Sentiment Analysis

The Deep Dive

NVO1.3/10

Novo Nordisk (NVO) is a pharmaceutical powerhouse, commanding leadership in the diabetes and obesity markets, fueled by its dominant GLP-1 franchise. The Q1 2026 results show strong reported sales growth of 32% YoY at CER, and the company raised its 2026 outlook, reflecting robust demand. However, a critical red flag for 10x growth potential is the explicit *4% decline in adjusted sales due to lower realized prices* and a *6% decline in adjusted operating profit* in Q1 2026. This confirms intens...

Full NVO Analysis

PFE4.0/10

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and Comirnaty contracts offer stability, but these are incremental gains for a company of Pfizer's scale....

Full PFE Analysis

Want More Comparisons?

Run any stock through our deep value analyzer.

Analyze Any Stock →View Top 100 →

Not Financial Advice

This comparison is for educational purposes only. We are not financial advisors. Always do your own research and consult a qualified financial advisor before making investment decisions.